Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Liver Diseases

  Free Subscription

Articles published in J Clin Oncol

Retrieve available abstracts of 35 articles:
HTML format

Single Articles

    May 2024
  1. FICHTINGER RS, Aldrighetti LA, Abu Hilal M, Troisi RI, et al
    Laparoscopic Versus Open Hemihepatectomy: The ORANGE II PLUS Multicenter Randomized Controlled Trial.
    J Clin Oncol. 2024;42:1799-1809.
    PubMed     Abstract available

    April 2024
  2. CHAVEZ-VILLA M, Ruffolo LI, Line PD, Dueland S, et al
    Emerging Role of Liver Transplantation for Unresectable Colorectal Liver Metastases.
    J Clin Oncol. 2024;42:1098-1101.

    March 2024
  3. GORDAN JD, Kennedy EB, Abou-Alfa GK, Beal E, et al
    Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.
    J Clin Oncol. 2024 Mar 19:JCO2302745. doi: 10.1200/JCO.23.02745.
    PubMed     Abstract available

    January 2024
  4. HUANG DQ, Hoang JK, Kamal R, Tsai PC, et al
    Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma.
    J Clin Oncol. 2024 Jan 4:JCO2300757. doi: 10.1200/JCO.23.00757.
    PubMed     Abstract available

    November 2023
  5. WANG G, Zhuo N, Liu Z
    Nonalcoholic Fatty Liver Disease May Be an Independent, Modifiable Risk Factor for Young-Onset Digestive Tract Cancers.
    J Clin Oncol. 2023;41:5070.

    June 2023
  6. OOSTEROM N, Gooskens SLM, Renfro LA, Perlman EJ, et al
    Severe Hepatopathy in National Wilms Tumor Studies 3-5: Prevalence, Clinical Features, and Outcomes After Reintroduction of Chemotherapy.
    J Clin Oncol. 2023 Jun 21:JCO2202555. doi: 10.1200/JCO.22.02555.
    PubMed     Abstract available

  7. PARK JH, Hong JY, Shen JJ, Han K, et al
    Increased Risk of Young-Onset Digestive Tract Cancers Among Young Adults Age 20-39 Years With Nonalcoholic Fatty Liver Disease: A Nationwide Cohort Study.
    J Clin Oncol. 2023;41:3363-3373.
    PubMed     Abstract available

    Rationale for Cotargeting Hepatocyte Growth Factor and Epidermal Growth Factor Receptor in Recurrent/Metastatic Head and Neck Cancer.
    J Clin Oncol. 2023 Jun 15:JCO2300460. doi: 10.1200/JCO.23.00460.

    Treating Cancer in People With HIV.
    J Clin Oncol. 2023 Jun 2:JCO2300737. doi: 10.1200/JCO.23.00737.
    PubMed     Abstract available

    May 2023
  10. EL ZARIF T, Nassar AH, Adib E, Fitzgerald BG, et al
    Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.
    J Clin Oncol. 2023 May 16:JCO2202459. doi: 10.1200/JCO.22.02459.
    PubMed     Abstract available

    April 2023
  11. LIN TA, Das A, McCaw Z, Ludmir EB, et al
    Determining the Efficacy of Pembrolizumab in Patients With Previously Treated Advanced Hepatocellular Carcinoma.
    J Clin Oncol. 2023 Apr 4:JCO2300072. doi: 10.1200/JCO.23.00072.

    March 2023
  12. SANDHYA L, Devi Sreenivasan N, Goenka L, Dubashi B, et al
    Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepatopancreaticobiliary, and Lung Cancer.
    J Clin Oncol. 2023 Mar 28:JCO2201997. doi: 10.1200/JCO.22.01997.
    PubMed     Abstract available

  13. OLOFSSON BAGGE R, Nelson A, Shafazand A, All-Eriksson C, et al
    Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial).
    J Clin Oncol. 2023 Mar 20:JCO2201705. doi: 10.1200/JCO.22.01705.
    PubMed     Abstract available

    December 2022
  14. LI SH, Mei J, Cheng Y, Li Q, et al
    Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study.
    J Clin Oncol. 2022 Dec 16:JCO2201142. doi: 10.1200/JCO.22.01142.
    PubMed     Abstract available

  15. YAU T, Zagonel V, Santoro A, Acosta-Rivera M, et al
    Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
    J Clin Oncol. 2022 Dec 13:JCO2200972. doi: 10.1200/JCO.22.00972.
    PubMed     Abstract available

  16. QIN S, Chen Z, Fang W, Ren Z, et al
    Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial.
    J Clin Oncol. 2022 Dec 1:JCO2200620. doi: 10.1200/JCO.22.00620.
    PubMed     Abstract available

    August 2022
  17. PENG Z, Fan W, Zhu B, Wang G, et al
    Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH).
    J Clin Oncol. 2022 Aug 3:JCO2200392. doi: 10.1200/JCO.22.00392.
    PubMed     Abstract available

    June 2022
  18. BEJJANI AC, Finn RS
    Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations.
    J Clin Oncol. 2022 Jun 1:JCO2102605. doi: 10.1200/JCO.21.02605.
    PubMed     Abstract available

  19. RAPHAEL MJ, Karanicolas PJ
    Regional Therapy for Colorectal Cancer Liver Metastases: Which Modality and When?
    J Clin Oncol. 2022 Jun 1:JCO2102505. doi: 10.1200/JCO.21.02505.
    PubMed     Abstract available

    May 2022
  20. CHIANG CH, Chiang CH, Chiang CH
    Are H1-Antihistamines Associated With a Lower Risk of Hepatocellular Carcinoma?
    J Clin Oncol. 2022 May 12:JCO2200179. doi: 10.1200/JCO.22.00179.

    March 2022
  21. SUTCUOGLU O, Ulas Kahya B, Ozdemir N, Yazici O, et al
    Can Systemic Control Be Achieved in the Treatment of Oligometastatic Hepatocellular Cancer With Hepatic Artery Infusion Fluorouracil, Leucovorin, and Oxaliplatin Treatment?
    J Clin Oncol. 2022 Mar 29:JCO2200047. doi: 10.1200/JCO.22.00047.

  22. JOHNSON PJ, Pinato DJ, Kalyuzhnyy A, Toyoda H, et al
    Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma.
    J Clin Oncol. 2022 Mar 28:JCO2102373. doi: 10.1200/JCO.21.02373.

  23. MEI J, Yu H, Qin L, Jia Z, et al
    FOLFOX-HAIC for Unresectable Large Hepatocellular Carcinoma: The Effectiveness Has Yet to be Determined.
    J Clin Oncol. 2022 Mar 22:JCO2102533. doi: 10.1200/JCO.21.02533.

    January 2022
  24. SHEN YC, Hsu HC, Lin TM, Chang YS, et al
    H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection.
    J Clin Oncol. 2022 Jan 19:JCO2101802. doi: 10.1200/JCO.21.01802.
    PubMed     Abstract available

    December 2021
  25. LYU N, Wang X, Li JB, Lai JF, et al
    Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).
    J Clin Oncol. 2021 Dec 14:JCO2101963. doi: 10.1200/JCO.21.01963.
    PubMed     Abstract available

  26. MULCAHY MF, Mahvash A, Pracht M, Montazeri AH, et al
    Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial.
    J Clin Oncol. 2021;39:3897-3907.
    PubMed     Abstract available

  27. TROBAUGH-LOTRARIO A, Katzenstein HM, Ranganathan S, Lopez-Terrada D, et al
    Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Children's Oncology Group (COG) AHEP0731 Study Committee.
    J Clin Oncol. 2021 Dec 7:JCO2100803. doi: 10.1200/JCO.21.00803.
    PubMed     Abstract available

  28. SALEM R
    Hepatic Arterial Infusion Chemotherapy for Large Hepatocellular Carcinoma: Ready for Prime Time?
    J Clin Oncol. 2021 Dec 2:JCO2102392. doi: 10.1200/JCO.21.02392.

    October 2021
  29. LI QJ, He MK, Chen HW, Fang WQ, et al
    Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.
    J Clin Oncol. 2021 Oct 14:JCO2100608. doi: 10.1200/JCO.21.00608.
    PubMed     Abstract available

    September 2021
  30. BOOTH CM, Berry SR
    Perioperative Chemotherapy for Resectable Liver Metastases in Colorectal Cancer: Do We Have a Blind Spot?
    J Clin Oncol. 2021 Sep 24:JCO2101972. doi: 10.1200/JCO.21.01972.

  31. LENTZ RW, Messersmith WA
    Transarterial Radioembolization in Patients With Unresectable Colorectal Cancer Liver Metastases.
    J Clin Oncol. 2021 Sep 20:JCO2101993. doi: 10.1200/JCO.21.01993.

  32. KANEMITSU Y, Shimizu Y, Mizusawa J, Inaba Y, et al
    Hepatectomy Followed by mFOLFOX6 Versus Hepatectomy Alone for Liver-Only Metastatic Colorectal Cancer (JCOG0603): A Phase II or III Randomized Controlled Trial.
    J Clin Oncol. 2021 Sep 14:JCO2101032. doi: 10.1200/JCO.21.01032.
    PubMed     Abstract available

  33. RAYSON D
    J Clin Oncol. 2021;39:2962-2963.

    July 2021
  34. KELLEY RK, Sangro B, Harris W, Ikeda M, et al
    Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
    J Clin Oncol. 2021 Jul 22:JCO2003555. doi: 10.1200/JCO.20.03555.
    PubMed     Abstract available

    June 2021
  35. QIN S, Bi F, Gu S, Bai Y, et al
    Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
    J Clin Oncol. 2021 Jun 29:JCO2100163. doi: 10.1200/JCO.21.00163.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.